Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, completed a $201.3 million public offering of common stock. Our firm advised Endocyte on the transaction. Endocyte's shares trade on the NASDAQ Global Market under the symbol "ECYT."
September 2018
Endocyte Completes $201.3 Million Public Offering
Lead Contacts
